Evidence map›Paper›PMID 33839999›Full record

ArticleNeurochemical research2021

Gastrodin Alleviates Cerebral Ischaemia/Reperfusion Injury by Inhibiting Pyroptosis by Regulating the lncRNA NEAT1/miR-22-3p Axis.

Heng-Sheng Zhang, Bo Ouyang, Xiong-Ying Ji, Mei-Fang Liu

Abstract read
PubMed Publisher
In one paragraph

Article in Neurochemical research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
34citing papers in PubMed, 1 pooled it
7.4field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

34 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Gastrodin: a comprehensive pharmacological review.Naunyn-Schmiedeberg's archives of pharmacology · 2024
    Review
  15. Article
  16. Article
  17. Review
  18. Review on pharmacological effects of gastrodin.Archives of pharmacal research · 2023
    Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Heng-Sheng Zhang *Department of Rehabilitation, Affiliated Nanhua Hospital, University of South China, Hengyang, 421002, Hunan, People's Republic of China.ORCID http://orcid.org/0000-0001-8134-3686
Bo Ouyang *Department of Traditional Chinese Medicine, Affiliated Nanhua Hospital, University of South China, No. 336 Dongfeng South Road, Zhuhui District, Hengyang, 421002, Hunan, People's Republic of China.
Xiong-Ying JiDepartment of Gastroenterology, Affiliated Nanhua Hospital, University of South China, Hengyang, 421002, Hunan, People's Republic of China.
Mei-Fang LiuDepartment of Traditional Chinese Medicine, Affiliated Nanhua Hospital, University of South China, No. 336 Dongfeng South Road, Zhuhui District, Hengyang, 421002, Hunan, People's Republic of China. 676664121@qq.com.
University of South China · CN

Funding

the Project of Hengyang science and Technology Bureau No.2016KS11
6 · The paper itself

Abstract

Cerebral ischaemia/reperfusion (I/R) injury-induced irreversible brain injury is a major cause of mortality and functional impairment in ageing people. Gastrodin (GAS), derived from the traditional Chinese herbal medicine Tianma, has been reported to inhibit the progression of stroke, but the mechanism whereby GAS modulates the progression of cerebral I/R remains unclear. The middle cerebral artery occlusion method was used as a model of I/R in vivo. Rats were pretreated with GAS by intraperitoneal injection 7 days before I/R surgery and were then treated with GAS for 7 days after I/R surgery. Additionally, an oxygen-glucose deprivation/reoxygenation model using neuronal cells was established in vitro to simulate I/R injury. 2,3,5-Triphenyltetrazolium chloride and Nissl staining were used to evaluate infarct size and neuronal damage, respectively. Lactate dehydrogenase release and cell counting kit-8 assays were used to assess neuronal cell viability. Enzyme-linked immunosorbent assay, qPCR, flow cytometry and western blotting were performed to analyse the expression levels of inflammatory factors (IL-1β, IL-18), lncRNA NEAT1, miR-22-3p, NLRP3 and cleaved caspase-1. Luciferase reporter experiments were performed to verify the association between lncRNA NEAT1 and miR-22-3p. The results indicated that GAS could significantly improve the neurological scores of rats and reduce the area of cerebral infarction. Meanwhile, GAS inhibited pyroptosis by downregulating NLRP3, inflammatory factors (IL-1β, IL-18) and cleaved caspase-1. In addition, GAS attenuated I/R-induced inflammation in neuronal cells through the modulation of the lncRNA NEAT1/miR-22-3p axis. GAS significantly attenuated cerebral I/R injury via modulation of the lncRNA NEAT1/miR-22-3p axis. Thus, GAS might serve as a new agent for the treatment of cerebral I/R injury.

Indexed as

AnimalsBenzyl AlcoholsBrainCell HypoxiaGlucoseGlucosidesInfarction, Middle Cerebral ArteryInflammationMaleMicroRNAsNeuronsNeuroprotective AgentsOxygenPyroptosisRatsRats, Sprague-DawleyBenzyl AlcoholsgastrodinGlucoseGlucosidesMicroRNAsMIRN22 microRNA, humanNEAT1 long non-coding RNA, humanNeuroprotective AgentsOxygenRNA, Long NoncodingCerebral ischaemia/reperfusionGastrodinLncRNA NEAT1MiR-22-3pPyroptosis

Identifiers

PMID33839999
OpenAlexW3155564300

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.